Author

N. Iwanaga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:protein structure· 1

Frequent Co-Authors

B. Beddingfield· 2 shared J. Kolls· 2 shared A. Furumoto· 1 shared A. Watanabe· 1 shared C. J. Roy· 1 shared G. Bix· 1 shared H. Liu· 1 shared H. Mukae· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. Beddingfield

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Analysis of chronic host-aspergilloma interactions using a novel mouse model

R. Hamashima, M. Tashiro, Y. Nakano, H. Namie, Y. Ito, T. Hirayama, K. Takeda, N. Iwanaga, K. Nishi, H. Liu, T. Takazono, T. Tanaka, A. Watanabe, Y. Komohara, A. Furumoto, , K. Izumikawa

This paper develops a novel mouse model of aspergilloma to study host-fungal interactions, revealing Th1/Th17 responses and angiogenesis induced by dead fungal hyphae.

bioRxiv · Oct 6, 2023 · PreprintMicrobiology

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection

B. Beddingfield, N. Iwanaga, P. P. Chapagain, W. Zheng, C. J. Roy, T. Y. Hu, J. Kolls, G. Bix

This paper explores ATN-161 as a potential therapy for SARS-CoV-2 by targeting the interaction between the spike protein and 5β1 integrin, alongside ACE2.

bioRxiv · Jun 15, 2020Microbiology

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

N. Iwanaga, L. Cooper, L. Rong, B. Beddingfield, J. Crabtree, R. A. Tripp, X. Qin, J. Kolls

This paper develops a modified ACE2-IgG1 fusion protein with enhanced in vivo activity against SARS-CoV2, showing improved lung bioavailability and viral neutralization.

bioRxiv · Jun 15, 2020 · PreprintImmunology